AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca PLC (LSE:AZN) fell 0.9% as analysts at Jefferies trimmed estimates and argued that clarity on margins may be needed for further stock upside.  The broker, has a buy rating on the Anglo-Swedish drugs maker but lowered its price target to 12,500p from 13,000p, as well as cutting EPS estimates by up to 5%.

AstraZeneca needs margin clarity for further upside says Jefferies

Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Investors Heavily Search AstraZeneca PLC (AZN): Here is What You Need to Know

Amazon

NVIDIA

As Thanksgiving festivities wind down and markets remain closed for a two-day hiatus, investors find themselves in a brief respite from the relentless pace of trading.

Best 3 Thanksgiving stocks to buy

AstraZeneca could pay up to $2 billion to Eccogene for the rights to an obesity drug candidate. That candidate could give patients a safer option than those that are available in the market today.

Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Astrazeneca (AZN) is a Strong Value Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for AstraZeneca's Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) which has been contemporaneously approved for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastat.

U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for AstraZeneca's Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) to Identify Patients with HR-Positive, HER2-Negative Advanced Breast Cancer

Li Auto Inc.

QUALCOMM

SoFi Technologies

This article is an excerpt from the InvestorPlace Digest newsletter. To get news like this delivered straight to your inbox, click here.

5 Growth Stocks to Buy for 2024

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the life sciences and healthcare sector. Evinova will prioritise bringing to market established and scaled digital technology solutio.

AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes

Barclays Capital has issued an optimistic assessment of AstraZeneca PLC (LSE:AZN)'s shares, recommending an "overweight" position with a target price of £135, a significant premium to the current market valuation of £101 per share.  The confidence in AZ, a major biopharmaceutical firm, stems partly from its recent third-quarter performance, which saw the company raising its full-year guidance to levels that align closely with Barclays' estimates.

AstraZeneca: Leading bank tells us why the stock is a core holding

Super Group SGHC Ltd

Wix.com

Stocks that crush their earnings estimates are supposed to go up. However, that's not always the case.

3 stocks that crushed earnings estimates and still tanked

AstraZeneca's Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) receives US FDA marketing approval for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN).

Third Success from Astex Drug Discovery Pharma Collaboration and Licence Agreements as AstraZeneca Receives US Marketing Approval for Cancer Drug Truqap (capivasertib)

AstraZeneca is making another go at developing a medicine like Ozempic. The U.K. pharma giant purchased licensing rights to a candidate in early-stage clinical trials.

AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock

AstraZeneca's (AZN) capivasertib gets approval in combination with Faslodex for HR-positive, HER2-negative metastatic breast cancer.

AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer

Sanofi

The CDC's move to increase availability of Beyfortus, a monoclonal antibody from Sanofi and AstraZeneca, comes as RSV cases rise in some parts of the country.

CDC expedites release of more doses of infant RSV drug from Sanofi, AstraZeneca amid shortage

AstraZeneca PLC (LSE:AZN) has secured US approval for a new breast cancer treatment, Truqap (capivasertib), to be used in combination with Faslodex (fulvestrant). It brings hope for a specific group of sufferers: adult women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic forms of the disease, who have specific genetic biomarkers (PIK3CA, AKT1, or PTEN).

AstraZeneca gets US sign-off for breast cancer combination

Chubb

Eaton

Novo Nordisk

NXP Semiconductors

Shell PLC

Investors in Eurozone stocks have been taken for a roller-coaster ride thus far this year. These stocks performed strongly during the first several months of 2023 as the pace of economic activity and company profits beat market expectations.

When Will It Again Be Safe To Invest In Eurozone Stocks?

The U.S. Food and Drug Administration on Thursday approved AstraZeneca's drug capivasertib in combination with an older drug, providing another treatment option for patients with the most common type of breast cancer.

US FDA approves AstraZeneca's breast cancer drug combination

The U.S. Centers for Disease Control and Prevention said on Thursday it has released more than 77,000 additional doses of Sanofi and AstraZeneca's respiratory syncytial virus (RSV) drug Beyfortus.

CDC releases 77,000 additional doses of Sanofi-AstraZeneca's RSV drug

AstraZeneca's (AZN) PACIFIC-2 study on Imfinzi fails to achieve statistical significance for the primary endpoint of progression-free survival.

AstraZeneca's (AZN) Imfinzi Early-Stage Lung Cancer Study Fails

AllianceBernstein Hld

Arbor Realty Trust

Ares Capital

Alexandria Real Estate Equities

BHP Billiton

British American Tobacco

CVS Health

Discover

Fifth Third Bancorp

Hasbro

Navient

NexPoint Residential Trust

Pfizer

Philip Morris

Vici Properties

March-April, 2022, UBS, Kiplinger, and Barron's analysts and reporters combined to list five sets of stocks sorted as: “Inflation Busters.” Those five articles revealed 48 equities, with 43 paying dividends.

13 Buyable Inflation-Busting November Dividend Stocks

AstraZeneca said a trial of its Imfinzi drug as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy (CRT) failed to make a statistically significant difference to patients. Primary endpoint for the trial [PACIFIC -2] was progression-free survival (PFS) versus CRT alone for the treatment of patients with unresectable, stage III non-small cell lung cancer (NSCLC).

AstraZeneca to learn from latest Imfinzi trial after endpoint not met

Drugmaker AstraZeneca said on Tuesday its cancer drug Imfinzi administered with chemoradiotherapy failed to meet its main goal in a late-stage trial to treat unresectable, Stage 3 non-small cell lung cancer.

AstraZeneca's Imfinzi plus chemoradiotherapy fail main goal in late stage trial

Recently, Zacks.com users have been paying close attention to Astrazeneca (AZN). This makes it worthwhile to examine what the stock has in store.

Here is What to Know Beyond Why AstraZeneca PLC (AZN) is a Trending Stock

BioNTech SE

Boston Scientific

Senti Biosciences Inc

Eccogene out-licenses global rights for its GLP-1 agonist to AstraZeneca in a $2 billion deal. Biotheus sells ex-China rights for a bispecific antibody candidate to BioNTech for $55 million upfront. WuXi XDC conducts a $500 million Hong Kong IPO to expand its manufacturing capacity for ADCs and bioconjugates.

Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal

AstraZeneca on Friday said it was prioritizing the U.S. market for additional doses of its respiratory syncytial virus (RSV) drug Beyfortus, which was approved in July to prevent the disease in infants and toddlers, as a surge of cases is outpacing supply.

AstraZeneca prioritizes US for RSV drug amid surge in cases

News for AstraZeneca Stock (AZN)